EditorialInside the labs of Afrigen Biologics and Vaccines, a Cape Town biotechnology company that has ambitions to be a major producer of new mRNA vaccines, in South Africa, Sept. 27, 2021. (Sydelle Willow Smith/The New York Times)
EditorialInside the labs of Afrigen Biologics and Vaccines, a Cape Town biotechnology company that has ambitions to be a major producer of new mRNA vaccines, in South Africa, Sept. 27, 2021. (Sydelle Willow Smith/The New York Times)